ArticleClinical rheumatology2026
Association of urinary albumin-to-creatinine ratio with all-cause and cardiovascular disease mortality risk in patients with osteoarthritis: a prospective cohort study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is associated with increased all-cause and cardiovascular disease (CVD) mortality, yet simple biomarkers for risk stratification are lacking. UACR, which measures the albumin-to-creatinine ratio in urine, is a known marker for kidney injury and mortality prediction in different populations, but its prognostic value in OA remains unknown.
methodsThis prospective cohort study included 3061 US adults with OA from the National Health and Nutrition Examination Survey 2005-2018. Weighted Cox proportional hazards models, Kaplan-Meier curves, subgroup analyses, and multiple imputation sensitivity analyses were performed.
resultsDuring a median follow-up period of 81.3 months, there were 526 deaths from all causes and 147 deaths from CVD disease. Higher UACR was associated with stepwise increased mortality (log-rank P < 0.001). For every 100 mg/g rise in UACR, the fully adjusted models showed HRs of 1.04 (95% CI 1.03-1.06) for mortality from all causes and 1.04 (1.00-1.07) for mortality due to CVD. When compared to a UACR of less than 30 mg/g, the HRs for UACR levels between 30-300 mg/g and 300 mg/g or more were 2.01 (1.54-2.63) and 4.29 (2.66-6.93) for all-cause mortality and 2.28 (1.48-3.51) and 3.84 (1.87-7.90) for CVD mortality (both P for trend < 0.001). Stronger associations were noted among females and those with lung disease (P for interaction = 0.030 and < 0.001, respectively). Sensitivity analyses confirmed robustness.
conclusionsElevated UACR is independently and incrementally associated with higher all-cause and CVD mortality in OA patients, especially in women and those with comorbid lung disease. UACR may function as an uncomplicated, non-invasive tool for predicting risk in OA. Key Points • First nationally representative cohort study linking UACR with mortality in osteoarthritis patients. • Elevated UACR independently predicted higher all-cause and cardiovascular mortality in a dose-response manner. • Stronger associations were found in females and those with comorbid lung disease. • UACR may serve as a simple, non-invasive tool for mortality risk stratification in osteoarthritis.
Indexed as
Identifiers
42547678What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.